Renalytix (LON:RENX) Shares Climb 1.8% – Still a Buy?

Renalytix Plc (LON:RENX) shot up 1.8% during trading on Thursday. The stock traded as high as GBX 5.90 and last traded at GBX 5.56. Approximately 2,739,277 shares were traded during mid-day trading, an increase of 154% from the average session volume of 1,079,704 shares. The stock had previously closed at GBX 5.47.

Renalytix Stock Up 1.8%

The firm has a market cap of £37.30 million, a PE ratio of -1.39 and a beta of 1.71. The business’s 50 day moving average price is GBX 5.17 and its 200 day moving average price is GBX 3.26. The company has a debt-to-equity ratio of -483.33, a current ratio of 1.57 and a quick ratio of 2.42.

Insiders Place Their Bets

In related news, insider Christopher H. B. Mills sold 1,166,667 shares of Renalytix stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of GBX 6, for a total value of £70,000.02. Insiders own 5.99% of the company’s stock.

Renalytix Company Profile

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).